VERASTEM INC (VSTM) Fundamental Analysis & Valuation

NASDAQ:VSTM • US92337C2035

6.3 USD
-0.08 (-1.25%)
At close: Mar 9, 2026
6.3 USD
0 (0%)
After Hours: 3/9/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VSTM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VSTM. VSTM was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of VSTM have multiple concerns. VSTM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. VSTM Profitability Analysis

1.1 Basic Checks

  • VSTM had negative earnings in the past year.
  • VSTM had a negative operating cash flow in the past year.
  • VSTM had negative earnings in each of the past 5 years.
  • VSTM had a negative operating cash flow in each of the past 5 years.
VSTM Yearly Net Income VS EBIT VS OCF VS FCFVSTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • VSTM has a Return On Assets of -85.00%. This is in the lower half of the industry: VSTM underperforms 69.17% of its industry peers.
  • VSTM's Return On Equity of -366.23% is on the low side compared to the rest of the industry. VSTM is outperformed by 73.60% of its industry peers.
Industry RankSector Rank
ROA -85%
ROE -366.23%
ROIC N/A
ROA(3y)-90.67%
ROA(5y)-83.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VSTM Yearly ROA, ROE, ROICVSTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • VSTM has a Gross Margin of 82.86%. This is amongst the best in the industry. VSTM outperforms 86.13% of its industry peers.
  • In the last couple of years the Gross Margin of VSTM has grown nicely.
  • The Profit Margin and Operating Margin are not available for VSTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.08%
GM growth 5Y5.71%
VSTM Yearly Profit, Operating, Gross MarginsVSTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. VSTM Health Analysis

2.1 Basic Checks

  • VSTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VSTM has been increased compared to 1 year ago.
  • VSTM has more shares outstanding than it did 5 years ago.
  • VSTM has a better debt/assets ratio than last year.
VSTM Yearly Shares OutstandingVSTM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
VSTM Yearly Total Debt VS Total AssetsVSTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -6.47, we must say that VSTM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of VSTM (-6.47) is worse than 65.13% of its industry peers.
  • A Debt/Equity ratio of 1.42 is on the high side and indicates that VSTM has dependencies on debt financing.
  • VSTM's Debt to Equity ratio of 1.42 is on the low side compared to the rest of the industry. VSTM is outperformed by 77.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Altman-Z -6.47
ROIC/WACCN/A
WACC9.01%
VSTM Yearly LT Debt VS Equity VS FCFVSTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 3.09 indicates that VSTM has no problem at all paying its short term obligations.
  • VSTM's Current ratio of 3.09 is on the low side compared to the rest of the industry. VSTM is outperformed by 63.97% of its industry peers.
  • VSTM has a Quick Ratio of 3.07. This indicates that VSTM is financially healthy and has no problem in meeting its short term obligations.
  • VSTM has a worse Quick ratio (3.07) than 62.04% of its industry peers.
Industry RankSector Rank
Current Ratio 3.09
Quick Ratio 3.07
VSTM Yearly Current Assets VS Current LiabilitesVSTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. VSTM Growth Analysis

3.1 Past

  • VSTM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.43%, which is quite good.
  • Looking at the last year, VSTM shows a very strong growth in Revenue. The Revenue has grown by 209.14%.
  • Measured over the past years, VSTM shows a very negative growth in Revenue. The Revenue has been decreasing by -18.97% on average per year.
EPS 1Y (TTM)13.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.41%
Revenue 1Y (TTM)209.14%
Revenue growth 3Y128.24%
Revenue growth 5Y-18.97%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 21.92% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, VSTM will show a very strong growth in Revenue. The Revenue will grow by 82.24% on average per year.
EPS Next Y41.93%
EPS Next 2Y29.43%
EPS Next 3Y30.46%
EPS Next 5Y21.92%
Revenue Next Year263.25%
Revenue Next 2Y169.12%
Revenue Next 3Y126.23%
Revenue Next 5Y82.24%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VSTM Yearly Revenue VS EstimatesVSTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
VSTM Yearly EPS VS EstimatesVSTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. VSTM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VSTM. In the last year negative earnings were reported.
  • Also next year VSTM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VSTM Price Earnings VS Forward Price EarningsVSTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VSTM Per share dataVSTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • VSTM's earnings are expected to grow with 30.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.43%
EPS Next 3Y30.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VSTM Dividend Analysis

5.1 Amount

  • VSTM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VSTM Fundamentals: All Metrics, Ratios and Statistics

VERASTEM INC

NASDAQ:VSTM (3/9/2026, 8:00:02 PM)

After market: 6.3 0 (0%)

6.3

-0.08 (-1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04
Earnings (Next)05-11
Inst Owners95.27%
Inst Owner Change22.7%
Ins Owners0.66%
Ins Owner Change1.18%
Market Cap486.05M
Revenue(TTM)30.91M
Net Income(TTM)-209.47M
Analysts85.33
Price Target16.96 (169.21%)
Short Float %24.91%
Short Ratio10.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.44%
Min EPS beat(2)-108.2%
Max EPS beat(2)7.32%
EPS beat(4)2
Avg EPS beat(4)-15.34%
Min EPS beat(4)-108.2%
Max EPS beat(4)48.42%
EPS beat(8)4
Avg EPS beat(8)-7.3%
EPS beat(12)6
Avg EPS beat(12)-10.77%
EPS beat(16)8
Avg EPS beat(16)-6.02%
Revenue beat(2)2
Avg Revenue beat(2)52.19%
Min Revenue beat(2)9.65%
Max Revenue beat(2)94.73%
Revenue beat(4)3
Avg Revenue beat(4)22.8%
Min Revenue beat(4)-100%
Max Revenue beat(4)94.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.1%
PT rev (3m)3.91%
EPS NQ rev (1m)3.64%
EPS NQ rev (3m)7.21%
EPS NY rev (1m)0.53%
EPS NY rev (3m)0.54%
Revenue NQ rev (1m)-3.73%
Revenue NQ rev (3m)7.05%
Revenue NY rev (1m)-2.31%
Revenue NY rev (3m)6.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.72
P/FCF N/A
P/OCF N/A
P/B 8.5
P/tB 11.92
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0.4
BVpS0.74
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85%
ROE -366.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.86%
FCFM N/A
ROA(3y)-90.67%
ROA(5y)-83.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.08%
GM growth 5Y5.71%
F-Score6
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1321.98%
Cap/Sales 31.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.09
Quick Ratio 3.07
Altman-Z -6.47
F-Score6
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)476.56%
Cap/Depr(5y)304.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.41%
EPS Next Y41.93%
EPS Next 2Y29.43%
EPS Next 3Y30.46%
EPS Next 5Y21.92%
Revenue 1Y (TTM)209.14%
Revenue growth 3Y128.24%
Revenue growth 5Y-18.97%
Sales Q2Q%N/A
Revenue Next Year263.25%
Revenue Next 2Y169.12%
Revenue Next 3Y126.23%
Revenue Next 5Y82.24%
EBIT growth 1Y-47.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y45.99%
EBIT Next 5Y14.17%
FCF growth 1Y-40.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.25%
OCF growth 3YN/A
OCF growth 5YN/A

VERASTEM INC / VSTM FAQ

Can you provide the ChartMill fundamental rating for VERASTEM INC?

ChartMill assigns a fundamental rating of 2 / 10 to VSTM.


What is the valuation status for VSTM stock?

ChartMill assigns a valuation rating of 1 / 10 to VERASTEM INC (VSTM). This can be considered as Overvalued.


What is the profitability of VSTM stock?

VERASTEM INC (VSTM) has a profitability rating of 1 / 10.


What is the financial health of VERASTEM INC (VSTM) stock?

The financial health rating of VERASTEM INC (VSTM) is 2 / 10.